Takeda Pharmaceutical Company Limited or Grifols, S.A.: Who Invests More in Innovation?

Takeda vs. Grifols: A Decade of R&D Investment

__timestampGrifols, S.A.Takeda Pharmaceutical Company Limited
Wednesday, January 1, 2014180753000382096000000
Thursday, January 1, 2015224193000345927000000
Friday, January 1, 2016197617000312303000000
Sunday, January 1, 2017288320000325441000000
Monday, January 1, 2018240661000368298000000
Tuesday, January 1, 2019276018000492381000000
Wednesday, January 1, 2020294216000455833000000
Friday, January 1, 2021354881000526087000000
Saturday, January 1, 2022361140000633325000000
Sunday, January 1, 2023330551000729924000000
Monday, January 1, 2024729924000000
Loading chart...

Unveiling the hidden dimensions of data

Innovation Investment: A Tale of Two Giants

In the competitive world of pharmaceuticals, innovation is key. Takeda Pharmaceutical Company Limited and Grifols, S.A. are two industry titans, each with a unique approach to research and development (R&D) investment. Over the past decade, Takeda has consistently outpaced Grifols, investing nearly 1,700% more in R&D annually. From 2014 to 2023, Takeda's R&D expenses surged from approximately $382 billion to $730 billion, reflecting a robust commitment to innovation. In contrast, Grifols' investment grew from $181 million to $331 million, a commendable increase but dwarfed by Takeda's scale. This disparity highlights Takeda's strategic focus on pioneering new treatments and therapies. As we look to the future, the question remains: will Grifols ramp up its investment to compete with Takeda's innovation-driven growth?

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025